A Multicenter Pilot Study of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation With in-Vivo T-Cell Depletion to Evaluate the Role of NK Cells and KIR Mis-Matches in Relapsed or Refractory High-Risk Neuroblastoma.

Trial Profile

A Multicenter Pilot Study of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation With in-Vivo T-Cell Depletion to Evaluate the Role of NK Cells and KIR Mis-Matches in Relapsed or Refractory High-Risk Neuroblastoma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Busulfan (Primary) ; Fludarabine (Primary) ; Ciclosporin; Ciclosporin; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
  • Indications Graft-versus-host disease; Neuroblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Oct 2015 Status changed from discontinued to withdrawn prior to enrolment, according to ClinicalTrials.gov record.
    • 12 Aug 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 18 Jan 2011 Planned End Date changed from 1 Jun 2011 to 1 Jun 2012 as reported by inicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top